Bio-Connect

Anti-IL-5 [Sch 55700 (Reslizumab)]

AB04156-13.12-BT
Absolute Antibody
ApplicationsNeutralisation/Blocking
Product group Antibodies
ReactivityHuman
TargetIL5
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    Absolute Antibody
  • Product Name
    Anti-IL-5 [Sch 55700 (Reslizumab)]
  • Delivery Days Customer
    9
  • Antibody Specificity
    This antibody recognizes and binds human interleukin-5, a key cytokine responsible for the differentiation, maturation, recruitment and activation of human eosinophils. This antibody specifically recognizes amino acids 89-93 (ERRRV) of human IL-5 and is c
  • Application Supplier Note
    This antibody is a humanized version of anti-IL5 rat antibody 39D10. The binding affinity of the original human IgG4 version of this antibody was measured using Biacore analysis and it was reported that this antibody bound human IL-5 with a Kd= 81pM (PMID: 7613159). This antibody was capable of inhibiting the binding of hIL-5 to Ba/F3 cells and IL5 induced proliferation of human erythroleukemic cell line TF-1 with an EC50 of 45pM. The in vivo activity of this antibody was studied in Ascaris responsive monkeys, and it was reported that this antibody inhibits eosinophilia in allergic animal models with an extended biological duration (PMID: 7613159). This antibody was active against lung eosinophilia in allergic monkeys and mice and against pulmonary eosinophilia and airway hyperresponsiveness in allergic guinea pigs. It was reported that this antibody did not cause immunosuppression in guinea pigs (PMID: 9698918). It also blocks the pulmonary eosinophilia and neutrophilia caused by tracheal injection of hIL-5 in guinea pigs. In allergic rabbits, this antibody blocks cutaneous eosinophilia. In allergic cynomolgus monkeys, a single dose of this antibody (0.3 mg/kg i.v.) blocks the pulmonary eosinophilia caused by antigen challenge for up to six months (PMID: 10514907). A study was also conducted to determine the effect of this antibody in patients with severe persistent asthma (PMID: 12649124). Clinical trials were conducted with this antibody to reduce asthma exacerbations, control asthma-related symptoms and improve pulmonary function in patients with eosinophilic asthma (PMID: 26372797).
  • Applications
    Neutralisation/Blocking
  • Certification
    Research Use Only
  • Clonality
    Monoclonal
  • Clone ID
    Sch 55700 (Reslizumab)
  • Gene ID3567
  • Target name
    IL5
  • Target description
    interleukin 5
  • Target synonyms
    B-cell differentiation factor I; colony-stimulating factor, eosinophil; EDF; eosinophil differentiation factor; IL-5; interleukin-5; T-cell replacing factor; TRF
  • Host
    Human
  • Isotype
    IgG4
  • Protein IDP05113
  • Protein Name
    Interleukin-5
  • Reactivity
    Human
  • Storage Instruction
    -20°C,2°C to 8°C
  • UNSPSC
    12352203